Table 2 Clinical features of patients... | American Society of Hematology

Table 2

Clinical features of patients with AA stratified by the presence/absence of non-PIGA somatic mutations

	Somatic mutation (n = 29)		No somatic mutation (n = 121)		P
	No.	%	No.	%	P
Sex					.5
Male	16	55	55	46
Female	13	45	66	54
Age at diagnosis, years					.4
Median	44		41
Range	27-83		11-87
Age at sampling, years					.2
Median	47		43
Range	28-83		17-87
Disease duration, months*					.04
Median	37		8
Range	0-305		0-605
Severity of AA					.7
Very severe	2	7	21	17
Severe	10	35	41	34
Nonsevere	16	55	49	41
Other†	1	3	10	8
PNH clone					.3
None	18	62	67	55
Subclinical	5	17	31	26
Moderate	1	3	13	11
Large	5	17	10	8
MDS/AML evolution					.001
Yes	11	38	6	5
No	18	62	115	94
IST					.5
Yes	22	76	85	70
No	7	24	36	30

	Somatic mutation (n = 29)		No somatic mutation (n = 121)		P
	No.	%	No.	%	P
Sex					.5
Male	16	55	55	46
Female	13	45	66	54
Age at diagnosis, years					.4
Median	44		41
Range	27-83		11-87
Age at sampling, years					.2
Median	47		43
Range	28-83		17-87
Disease duration, months*					.04
Median	37		8
Range	0-305		0-605
Severity of AA					.7
Very severe	2	7	21	17
Severe	10	35	41	34
Nonsevere	16	55	49	41
Other†	1	3	10	8
PNH clone					.3
None	18	62	67	55
Subclinical	5	17	31	26
Moderate	1	3	13	11
Large	5	17	10	8
MDS/AML evolution					.001
Yes	11	38	6	5
No	18	62	115	94
IST					.5
Yes	22	76	85	70
No	7	24	36	30

Time interval between the initial diagnosis and date of sampling.

Included pure red cell aplasia, acquired amegakaryocytic thrombocytopenia, and AA with hemolytic PNH.